Collaboration Aimed At Accelerating Development Of Lab Grown Corneas

BSF Enterprise PLC Partners with University of Montreal to Develop Advanced Corneal Treatment

Collaboration Aimed at Accelerating Development of Lab-Grown Corneas

London, UK – January 12, 2023

BSF Enterprise PLC, the London-based biotech company, announced today a partnership with the University of Montreal to collaborate on the development of a novel treatment for corneal damage. The partnership seeks to leverage the expertise of both organizations in the field of regenerative medicine.

Kerato Ltd, a subsidiary of BSF Enterprise PLC and a pioneer in lab-grown corneal tissue replacement, will lead the research and development efforts under this collaboration. Kerato's proprietary technology enables the production of biocompatible corneas that can potentially restore vision in patients with corneal damage.

The University of Montreal, renowned for its research in ophthalmology, will provide scientific and technical support to the project. The university's team of experts will contribute their knowledge in tissue engineering, cell biology, and corneal transplantation.

"We are excited to partner with the University of Montreal, a world-leading institution in ophthalmic research," said Dr. Mark Lee, CEO of BSF Enterprise PLC. "This collaboration will accelerate the development of our lab-grown cornea technology and bring us closer to our goal of providing a life-changing treatment for patients with corneal damage."

The partnership is expected to yield significant advancements in the treatment of corneal diseases and injuries. By combining the expertise of Kerato and the University of Montreal, the team aims to develop a safe, effective, and accessible solution for patients worldwide.